Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase II trial of bemcentinib/pembrolizumab combination in patients with advanced NSCLC and melanoma

Nov. 28, 2018

Preclinical results of EAGLE technology targeting glyco-immune checkpoints for cancer treatment

Nov. 28, 2018

New deep vein thrombosis model allows real-time in vivo imaging

Nov. 28, 2018

Preclinical evaluation of zifaxaban, an oral inhibitor of factor Xa for thromboembolic diseases

Nov. 28, 2018

Spark Therapeutics to begin phase I/II study of SPK-8016 gene therapy in hemophilia A

Nov. 28, 2018

Bile acid receptor implicated in hepatic encephalopathy due to liver cirrhosis

Nov. 28, 2018

New phase I trial explores nasal administration of foralumab in healthy volunteers

Nov. 28, 2018

Vertex reports phase III data on VX-659 triple combination regimen for cystic fibrosis

Nov. 28, 2018

FDA clears IND for PBCAR-0191 allogeneic CAR T product candidate

Nov. 28, 2018

First-in-human data for MK-4280 alone or in combination with pembrolizumab

Nov. 28, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 16, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...